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S. Cardoso).1. Introduction
Acute liver failure (ALF) is a rare condition characterized by new and
rapidly evolving hepatic dysfunction associated with neurologic dysfunc-
tion and coagulopathy. It is more frequent in young individuals and its
etiologies vary geographically, with impact on both clinical course and
outcomes. Throughout the last decades, ALF outcomes have been improv-
ing in the context of the optimized overall management. However, its
Table 1
ALF phenotypes
Hyperacute (within 7 d) Acute (8-28
d)
Subacute (5-26 wk)
Etiology example Acetaminophen DILI, hepatitis A/E Hepatitis B Non-acetaminophen DILI
Transaminases +++ ++ +
Bilirubin + ++ +++
INR +++ ++ +
Cerebral edema High risk High risk Low risk
Survival without LT High Intermediate Low
DILI indicates drug-induced liver injury.
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prognostic criteria and without emergent liver transplantation (LT).
2. Deﬁnition and epidemiology
Acute liver failure deﬁnition has evolved throughout the time and
presently includes the following features: international normalized
ratio (INR) at least 1.5, neurologic dysfunctionwith any degree of hepat-
ic encephalopathy (HE), no preexisting cirrhosis, and disease course of
26 weeks or less [1]. Exceptions to this deﬁnition may be patients
with acute presentations of Wilson disease, autoimmune hepatitis, or
vertically transmitted hepatitis B if by the time of the newhepatic insult,
they also have underlying cirrhosis known for 26 weeks or less.
Acute liver failure has been subdivided into 3 phenotypes based on
the time between jaundice and HE onset (Table 1): hyperacute (within
7 days), acute (8-28 days), or subacute (5-26 weeks) [2]. However, the
clinical utility of this classiﬁcation has not been entirely clariﬁed be-
cause its impact on outcomes seems to be mostly associated with un-
derlying etiologies [3].
Acute liver failure incidence has been reported as fewer than 10
cases per million people per year in developed countries [4]. Its etiolo-
gies vary worldwide: whereas in Eastern developing countries, viruses
(mainly hepatitis A, B, or E) may account for up to 95% of all ALF cases,
the Western developed countries have reported more heterogeneous
causes of ALF [5]. In the United Kingdom and the United States, acet-
aminophen overdose has been the leading cause of ALF [3,6]. In other
parts of Europe (eg, Germany and Portugal), the most common causes
of ALFhave beennon-acetaminophendrug–induced liver injury, seroneg-
ative (indeterminate) liver injury, and viruses (mostly hepatitis B) [7,8].
Acute liver failure etiologies are summarized in Table 2 [1,3,4,9].
Acute liver failure outcomes have been improving throughout the
decades with overall hospital survival increasing from 17% in 1973 toTable 2
ALF etiologies
Viruses








Non-acetaminophen (eg, isoniazid, phenytoin, valproate, propylthiouracil,
nitrofurantoin)










MDMA indicates 3,4-methylenedioxy-N-methylamphetamine.1978 to 62% in 2004 to 2008 in a single center from the United Kingdom
[10]. In a multicenter registry from the United States in 1998 to 2010,
ALF2-year survival hasbeen reportedas 92% for liver transplant (LT) recip-
ients, 90% for acetaminophenoverdose spontaneous survivors, and76% for
non-acetaminophen spontaneous survivors [11]. This positive trend has
been attributed to the earlier recognition of this condition, the improve-
ment of the intensive care unit (ICU)management, and the developments
in emergent LT [10]. Overall, themost commoncauses of death inALFhave
been multiorgan failure (18%), liver failure (17%), and sepsis (12%) [11].
3. Pathophysiology and clinical manifestations
In ALF, the liver insult results in extensive death of hepatocytes with
activation of the innate immune system responses (Kupffer cells and
circulatingmonocytes) causing a large production of inﬂammatoryme-
diators. The “spill-over” of these inﬂammatorymediators into the circu-
lation ultimately leads to the systemic disturbances and clinical
manifestations of ALF [12]. An overwhelming systemic inﬂammatory
response syndrome (SIRS) is associated with the several organ failures
that may ensue.
In parallel to the proinﬂammatory response, a compensatory anti-
inﬂammatory response develops [13]. Although within the injured liver,
the production of anti-inﬂammatory mediators serves to dampen proin-
ﬂammatory responses, limit the extent of tissue injury, and promote
liver regeneration, their release into the systemic circulation is associated
with apredisposition to infection [14]. At this stage, circulatingmonocytes
may become functionally impaired and less able to respond to infectious
stimuli, a state often referred as immune paresis [15,16]. Consequently,
sepsis and multiorgan failure are frequently the cause of death in ALF. A
summary of clinical manifestations related to the organ failures that
may ensue in the context of ALF is presented in Table 3.
4. General management
The initialmanagement of acute liver injury (hepatitis) or ALF is sup-
portive with the objective to optimize conditions for the liver toTable 3
ALF organ failures
Organ failure Pathophysiology
Liver Hyperlactatemia: decreased lactate clearance
Hyperammonemia: decreased ammonia clearance
Coagulopathy: decreased synthesis of procoagulant and
anticoagulant factors
Hypoglycemia: decreased gluconeogenesis
Portal hypertension: may develop especially in subacute disease
Brain HE: circulating inﬂammatory mediators and hyperammonemia
Cerebral edema: inﬂammatory mediators from microglial cells
and glutamine accumulation in astrocytes
Cardiovascular Hypotension or shock especially if sepsis superimposes
Lungs Acute lung injury or ARDS: SIRS, sepsis, and/or ﬂuid overload
Kidneys AKI: SIRS, sepsis, and/or hypovolemia
Pancreas Acute pancreatitis: SIRS and/or drug toxicity (eg, acetaminophen)
Multi-organ
failure
SIRS or sepsis (immune paresis)
Table 4
Initial laboratory tests for acute liver injury or ALF
Assessment Test




INR, aPTT, ﬁbrinogen, factor V
AST, ALT, bilirubin, albumin, alkaline phosphatase, LDH, amylase
Creatinine, urea, sodium, chloride, potassium, calcium,
magnesium, phosphorus, creatine kinase
Etiology
(serum or urine)
HAV IgM, HBsAg, HBc IgM, anti-HCV, anti-HEV, CMV IgM,
EBV IgM, HSV IgM, VZV IgM, anti-HIV
Ceruloplasmin, copper





aPTT indicates activated partial thromboplastin time; AST, asparte aminotransferase; ALT,
alanine aminotransferase; LDH, lactate dehydrogenase; HAV, hepatitis A virus; HBs, hepa-
titis B virus surface antigen; HBc, hepatitis B virus core antibody; HCV, hepatitis C virus;
HEV, hepatitis E virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HSV, herpes sim-
plex virus; VZV, varicella zoster virus; HIV, human immunodeﬁciency virus.
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Although most patients with acute liver injury may be managed in a
regular ward, patients with ALF should be referred to the ICU, ideally
one in a center capable of providing emergent LT, as soon as possible
as they may deteriorate quickly [1].
The initial diagnostic approach should be directed at detecting and
assessing the severity of hepatitis, HE, coagulopathy, and other organ fail-
ures. Clinical history taking, if possible, may be important to understand
the time between jaundice and HE onset, etiology factors (eg, alcohol in-
take, viral infection, drugs,mushroom, or tisane ingestion), and suspected
or known previous liver disease. Physical examination allows to detect
signs of organ failures and should include a mental status evaluation
(West-Haven criteria for overt HE and, if feasible, a neuropsychological
test for covert HE) and a search for stigmata of chronic liver disease. A
list of useful initial laboratory tests is displayed in Table 4. Abdominal im-
aging with ultrasonography (with Doppler studies) or computed tomo-
graphic (CT) scan (with intravenous contrast if safe) helps to exclude
features of chronic liver disease and biliary, pancreatic, or other intra-
abdominal pathology that could be the origin or contribute to the liver
failure. Liver biopsy (transcutaneous or transjugular) should be consid-
eredwhenever the etiology remains unclear andhistopathology informa-
tionmayhelp to changemanagement decisions, including LT assessment.4.1. General therapeutic approach
4.1.1. Hemodynamics
Patients with ALF are often volume depleted at presentation and re-
quire ﬂuid resuscitation. As inmany other hypovolemic syndromes, crys-
talloids should be the initial ﬂuids of choice, with normal saline (sodium
chloride 0.9%) being the most frequently in use [17]. Nevertheless, it
may be considered the use of a chloride-restrictive solution (eg, Plasma-Table 5
NAC protocols in ALF
Route and dosage [1,30]
Oral or enteral Loading dose of 140 mg/kg i
Intravenous Loading dose of 150 mg/kg i
by 100 mg/kg in glucose 5%
Length of therapy [1,30]
Controversy exists but at least a 72-h period irrespective of route has been suggested. A d
clinical improvement of patients has also been suggested.
More frequent adverse effects [1,30]
Nausea, vomiting, ﬂushing, rash, dyspnea, tachycardia, edema, anaphylactoid reactionLyte 148, Hartmann's solution) as it has been shown in patients with
acute illness that it may decrease the risk of metabolic acidosis and
acute kidney injury (AKI) [18,19]. In a non-ICU setting, some of the sim-
plest parameters can be used as targets for the initial ﬂuid replenishment
(while avoiding ﬂuid overload), for example, mean arterial pressure at
least 60 to 65 mm Hg, urine output at least 0.5 mL kg−1 h−1, and lactate
2 mmol/L or less.
On the contrary, patients with congestive hepatitis (eg, heart failure)
may be ﬂuid overloaded and diureticsmay help to improve liver function.
4.1.2. Hepatic encephalopathy
The correction of all factors that may contribute to the acute confu-
sion (eg, dehydration, infection, serum ions derangements) is important
for HE treatment. With this objective, sedative medications should be
avoided, except in situations deemed necessary (eg, agitation,
periendotracheal intubation for progressive HE). To exclude intracranial
pathology, a CT scan needs to be considered. Regular oral or enteral
feeding should be maintained whenever feasible [20]. Lactulose may
add to these patients' transplant-free survival, but careful should be
taken with possible abdominal distension [21]. L-Ornithine-L-aspartate
has not shown beneﬁt to neither HE grade nor overall survival [22].
4.1.3. Coagulopathy
In ALF, overall hemostasis as measured by thromboelastography has
been shown to be normal by several compensatory mechanisms, even
in patients with markedly elevated INR [23]. In the absence of active
bleeding or invasive procedure, it is not advisable to correct the INR
with fresh-frozen plasma, because clinically signiﬁcant blood loss is
rare and correction obscures trends in the INR, an important marker of
prognosis [1]. Nevertheless, vitamin K deﬁciency may be present in a
minority of patients with ALF; thus, vitamin K supplementation may
be used at least once [1,24].
In ALF, bleeding due to ﬁbrinolysis has been found to be limited due to
high levels of plasminogen activator inhibitor-1 [25]. In the absence of ac-
tive bleeding or invasive procedure, the platelet count should be main-
tained at least above the appropriate spontaneous bleeding threshold.
4.1.4. Infection
Acute liver failure risk of immune paresis increases susceptibility to
infection which may preclude emergent LT. Therefore, surveillance for
infection (including chest radiography and periodic cultures of sputum,
urine, and blood) should be undertaken, while maintaining a low
threshold for starting antimicrobial therapy [1]. Prophylactic antimicro-
bials have not been proven to improve 21-day survival in ALF [26]. Nev-
ertheless, the development of grade III-IV HE or SIRS has been
associated with infection and worse outcomes [27,28].
4.2. Etiology-speciﬁc therapeutic approach
4.2.1. Acetaminophen
N-acetylcysteine (NAC)has been largely used as an antidote for acet-
aminophen intoxication. Its mechanism of action has to do mainly with
glutathione replenishment, a crucial molecule for acetaminophen de-
toxiﬁcation in the liver [29,30]. In ALF, NAC use has been shown ton glucose 5%, followed by 70 mg/kg in glucose 5% every 4 h × 17 doses (overall 72 h)
n glucose 5% for 15 min, followed by 50 mg/kg in glucose 5% for 4 h, and followed
for 16 h (overall 20 h)
ecision to stop based on consistent
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[31]. Although reported more effective within 48 hours of acetamino-
phen ingestion, NAC is currently being started in many centers when
acetaminophen intoxication is suspected (eg, reported history of acet-
aminophen intake outside dose normal range or transaminases ≥3500
IU/L, especially in an alcohol intake or fasting context), irrespective of
acetaminophen dose, time since ingestion, or acetaminophen serum
level because it is often difﬁcult to establish when was the initial drug in-
take or if that was a one-time ingestion or a staggered overdose [1,32].N-
acetylcysteine administration protocols are presented in Table 5.
4.2.2. Non-acetaminophen
In non–acetaminophen-related ALF, namely in drug-induced liver
injury or hepatitis B, NAC seems to play a therapeutic role also as it
has been shown to improve transplant-free survival when given during
early HE stages (grade I-II) [33,34]. These resultsmay be related to other
effects that have been attributed to NAC, for example, improving hemo-
dynamics and oxygen use and decreasing the risk of cerebral edema [26,
35]. The mechanism of such effects has not been cleared, but it may in-
volve reducing the production of proinﬂammatory cytokines (eg, IL-17),
scavenging of free radicals, or changes in the hepatic bloodﬂow [35-37].
Several ALF etiologies may require speciﬁc therapies, for example:
(1) consider antiviral therapy for hepatitis B virus, cytomegalovirus,
herpes simplex virus, or varicella zoster virus–related ALF; (2) consider
steroid therapy for autoimmune hepatitis–related ALF; (3) consider
penicillin G or silibinin in Amanita phalloides–related ALF; and (4) con-
sider emergent delivery for pregnancy-related ALF (eg, acute fatty
liver of pregnancy or hemolysis, elevated liver enzymes, and low plate-
lets [HELLP] syndrome) [1].
5. Intensive care management
Acute liver failuremay lead to several organ failures; therefore, ICU ad-
mission should be considered as early as possible, especially when HE is
being difﬁcult to control in a regular ward or coagulopathy is progressing.
In this context, supporting organ failures follows the rules of general ICU
patients but with some speciﬁcities, which deserve to be emphasized.
5.1. Acute lung injury
Acute lung injury may occur in patients with ALF, more often at a
later stage of their clinical course, namely with liver regeneration or
sepsis [4]. Although patients with acute respiratory distress syndrome
(ARDS)may require greater number of ventilator days, the requirement
for vasopressors or renal replacement therapy (RRT), ICU stay, andmor-
tality have been described as similar to patients without ARDS [38].
Management of ARDS in this context, albeit following general inten-
sive care rules, may be more difﬁcult because increasing positive end-
expiratory pressure may exacerbate cerebral edema or liver congestion
[39]. Nevertheless, ﬁnding the optimum positive end-expiratory pres-
sure for each patient may help to improve oxygenation while minimiz-
ing such adverse consequences [40,41].
5.2. Hemodynamics
Patients with ALF typically present with a hyperdynamic circulation
characterized by high cardiac output and low peripheral vascular resis-
tance, a pattern resembling that of sepsis. For patients who continue to
have hypotension despite volume repletion, noradrenaline is the pre-
ferred vasopressor, with or without adjunctive use of vasopressin or its
analogs [42].
Echocardiography or invasive hemodynamic monitoring (eg, Pulse
Contour Continuous Cardiac Output, Swan-Ganz catheter) should be
used to assess cardiac function and help titrate decisions on the doses
of ﬂuids and/or vasopressors. Elevated troponin levels have been associ-
ated with an increase in grade III-IV HE and overall mortality [43].Nevertheless, it is unclear whether that represents subclinical myocar-
dial ischemia or simply reﬂects metabolic stress [44].
Relative adrenal insufﬁciencymay be present and the use of steroids
has been associated with a decrease in noradrenaline dose and overall
mortality [45].
5.3. Acute kidney injury
Acute kidney injurymaydevelop in up to 70% of patientswithALF and
has been associatedwithworse overall survival [46]. Hyperphosphatemia
develops with AKI if there is impaired liver regeneration and has been as-
sociatedwith poorer outcomes [47]. Acute kidney injury is oftenmultifac-
torial andmore commonwith certain etiologies: ischemic hepatitis, acute
fatty liver of pregnancy, HELLP syndrome, heat stroke, hepatitis A virus,
or drug-induced liver injury due to acetaminophen, phenytoin,
trimethoprim-sulfamethoxazole, or macrolides [48].
In this context, classic indications for RRT initiation also apply, includ-
ing severe acidosis, hyperkalemia, anuria, and/or ﬂuid overload [49]. Fur-
ther indications may include the following: removal of toxic substances
(eg, acetaminophen, ammonia), difﬁcult to treat hyponatremia, or difﬁ-
cult to treat hyperthermia [50,51]. Continuous modes of RRT are pre-
ferred over intermittent ones because the latter have been associated
with increased risk of hemodynamic instability and cerebral edema [52].
5.4. Cerebral edema and intracranial hypertension
Cerebral edema incidence in patients with ALF has been decreasing
throughout the last decades [10]. This positive trend may reﬂect im-
provements in the preventive care and use of emergent LT [17].
In ALF, astrocyte swelling may result in cytotoxic brain edema which
may culminate in tonsillar herniation anddeath. Liver-brain proinﬂamma-
tory signaling mechanisms involve the transduction of systemically de-
rived cytokines aswell as the gliotoxic effects of ammonia and lactate [53].
Frequent neurologic examination (including pupils) and the use of
transcranial Doppler are simple strategies to monitor for signs of cere-
bral edema and intracranial pressure. On the contrary, CT ﬁndings com-
patible with intracranial hypertension often present too late in the
course of this condition. Invasive monitoring of intracranial pressure
has not been shown to improve these patients’ hospital survival [54].
Nevertheless, it is still not clear if patients with the highest risk for cere-
bral edema and intracranial hypertension (eg, ammonia N150 µmol/l,
vasopressors requirement, or RRT requirement) may beneﬁt from
such monitoring capacity [55].
The approach to cerebral edema and intracranial hypertension con-
sists of the following: (1) head of the bed greater than 30°; (2) minimize
patient stimulation; (3) sedation and invasive mechanical ventilation;
(4) treat fever (although active hypothermia has not been proven to pre-
vent cerebral edema and intracranial hypertension) [56,57]; (5) treat sei-
zures (although prophylaxis has unclear value) [1]; (6) aim for a mean
arterial pressure of at least 75 mm Hg with ﬂuids and/or vasopressors,
with the goal being to maintain an intracranial pressure less than
25 mm Hg and a cerebral perfusion pressure greater than 50 mm Hg;
(7) consider using RRT to promote more effective ammonia clearance
[51]; (8) aim for a serum sodium of 145 to 155 mmol/L with hypertonic
saline (3%-30% infusion) for prophylaxis in patients with grade III-IV HE
[58]; (9) consider usingmannitol (0.5-1 g/kg bolus) to transiently reduce
intracranial pressure when there is established intracranial hypertension
(repeat if serum osmolality b320mOsm/L) [59]; and (10) consider using
hyperventilation (aiming for a PCO2 25-30 mm Hg) in cases of
established intracranial hypertension despite optimized treatment to
try to delay the progression to tonsillar herniation [60].
5.5. Extracorporeal liver support systems
The rationale for using an extracorporeal liver support (ECLS) system
in ALF is to help maintain homeostasis while the liver regenerates (eg,
Table 6
King's College criteria in ALF
Acetaminophen-related ALF Non–acetaminophen-related ALF
(A) Single criterion (A) Single criterion
- pH b7.30 or lactate N3.0 mmol/L
after adequate ﬂuid resuscitation
- INR N6.5
(B) 3 criteria (B) 3 of 5 criteria
- Grade III-IV (West-Haven) HE - Age b10 or N40 y
- INR N6.5 - Time from jaundice to coma N7 d
- Creatinine N3.4 mg/dL - INR N3.5
- Bilirubin N17 mg/dL
- Unfavorable etiology: drug-induced
liver injury, Wilson disease, or
seronegative liver injury
29F.S. Cardoso et al. / Journal of Critical Care 39 (2017) 25–30ischemic hepatitis or acetaminophen-related ALF) or until an organ is
available for transplantation (all etiologies). An ideal ECLS system would
be one capable of assisting on 3 major liver functions: removal of toxins,
biosynthesis, and immune modulation [61]. However, none of the artiﬁ-
cial (depuration through membranes) or bioartiﬁcial (hepatocytes) sys-
tems available performs efﬁciently all of these functions [62,63].
Two artiﬁcial ECLS systems have been studied in ALF with random-
ized controlled trials: molecular adsorbent recirculating system
(MARS) and high-volume plasmapheresis (HVP). With MARS, blood is
dialyzed across an albumin-impregnated high-ﬂux dialysis membrane
(pores with 50 kDa) and against a dialysate with albumin. Subsequent-
ly, 2 sequential adsorbent columns containing activated charcoal and
anion exchange resin remove most of the water-soluble and albumin-
bound toxins. In a recent study, MARS has not been proven to improve
6-month survival in ALF [64]. However, a confounder may have been
the median listing-to-transplant time which was only 16 hours, with
75% of enrolled patients undergoing LT within 24 hours.
With HVP, patients' plasma is replaced by fresh-frozen plasma with
the objective of removing plasma cytokines and adhesionmolecules, re-
placing plasma factors, and potentially modulating the immune system.
In a recent study, HVP has been shown to signiﬁcantly improve hospital
survival, especially for patients with contraindications for LT [65]. Nev-
ertheless, a limitation to account for may have been the 12-year inclu-
sion period. With both MARS and HVP, adverse effects have been
reported as similar to standard therapy [64,65].
Several bioartiﬁcial ECLS systems have been clinically tested, for ex-
ample: HepatAssist (Arbios, formerly Circe, Waltham, Mass), ECLS de-
vice (ELAD; Vital Therapies, San Diego, Calif), modular ECLS system
(MELS; Charité, Berlin, Germany), bioartiﬁcial liver support system
(BLSS; Excorp Medical, Minneapolis, Minn), and Amsterdam Medical
Center bioartiﬁcial liver (AMCBAL; AMC, Amsterdam, the Netherlands)
[1]. Ameta-analysis has shown that these systems failed to improve sur-
vival in ALF [66]. Nevertheless, more well-designed clinical trials in
humans are likely needed to fully evaluate these systems efﬁcacy and
safety [67].6. Liver transplantation
Liver transplantation is the only deﬁnitive treatment for patients
with ALF. Overall survival after LT has been reported to be lower for pa-
tientswith ALF in comparison to patientswith cirrhosis until 1 year after
transplant, but it tends to be similar from then on [68]. In fact, most
deaths after LT for patients with ALF occur from infection during the
ﬁrst 3 postoperative months [4]. Nevertheless, survival after LT for ALF
has been improving throughout the last decades, with 21-day survival
reaching 96% for the period of 2006 to 2013 [69].
Cadaveric donor LThas been the norm inALF, but living-donor trans-
plant has been performed in some large-volume centers with accept-
able outcomes. Despite this, controversy remains in regard to ethical
issues, namely the risk of living-donor coercion and morbidity ormortality [70]. Another strategy to prevent waitlist mortality has been
auxiliary transplantation (partial graft as temporary support for native
liver regeneration), which has shown reasonable outcomes too [71].
In ALF, stratifying patients based on their risk of death without LT is
crucial to prioritize them for transplantation. King's College criteria have
been used worldwide for this purpose (Table 6) [72]. A recent meta-
analysis has revealed its prognostic ability in comparison with the
MELD score: for acetaminophen-related ALF, sensitivities were 58%
and 80%, respectively, and speciﬁcities were 89% and 53%, respectively;
for non-acetaminophen etiologies, sensitivities were 58% and 76%, re-
spectively, and speciﬁcities were 74% and 73%, respectively [73]. There-
fore, King's College criteria remain highly speciﬁc for acetaminophen-
related ALF, but less accurate for non-acetaminophen etiologies. Another
useful tool for prognostication of death without LT in patients with
hepatitis B–related ALF and grade III-IV HE may be the Clichy criteria.
According to this tool, a serum factor V level lower than 20% in patients
30 years or younger or lower than 30% in any other patients prognosti-
cates mortality with a positive predictive value of 82% and a negative
predictive value of 98% [74]. However, it has been shown that the Clichy
criteria perform worse than the King's College criteria overall [75].
Risk stratiﬁcation in ALF may be improved further if taking into ac-
count not only the probability of deathwithout LT but also the probabil-
ity of death after transplantation. Studies have suggested that some
characteristics were associated with an increased risk of death after
LT: male recipient, recipient older than 45 years, recipient on vasopres-
sors, ABO-incompatible transplant, and high-risk graft use [76,77].7. Conclusions
Acute liver failure diagnostic and therapeutic strategies have
evolved throughout the time and that has been associated with im-
proved outcomes. New advances in basic and clinical research may po-
tentiate even more such outcomes. Despite this, these patients' early
referral to an LT center, ICU timely treatment, and a comprehensive
multidisciplinary strategy in risk stratiﬁcation and selection for LT will
continue to be fundamental steps for a successful approach.References
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